As was described in the pivotal trial publication by Samuelson et al. [14 (link)], iStent inject trabecular micro-bypass consists of two titanium stents on a single injector, with each stent having 230 µm diameter, 360 µm height, and 80 µm central lumen diameter. Despite the micro-scale dimensions (approximately the size of the period on this page), each stent is known to be able to handle the entire aqueous outflow production of the human eye (up to 2.5 µl/min on average) [15 (link)]. In the present study, the iStent inject stents were implanted either after cataract surgery or as a standalone procedure. In either case, the stents were inserted ab internally 2–3 clock-hours apart through the trabecular meshwork into Schlemm’s canal, which facilitates up to 6 total clock-hours of outflow [16 (link)]. After implantation, stent positioning was confirmed gonioscopically, viscoelastic was removed, and the clear corneal incision was confirmed to be closed. In the weeks after surgery, patients instilled topical ciprofloxacin (Floxal®, Bausch&Lomb, Berlin, Germany, × 1 week) and topical anti-inflammatory medication (Dexamethasone, Bausch&Lomb, Berlin, Germany, × 4-week taper).